ClinicalTrials.gg
Not yet recruitingNCT07948356Updated Nov 19, 2026

Pre-Operative fSRS for Brain Metastases

An interventional study of Fractionated Stereotactic Radiosurgery (fSRS) and Neurosurgical Resection in Brain Metastasases, sponsored by Northwell Health. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Northwell Health · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies in Brain Neoplasms by Northwell Health — 8 open to participants now, 8 under way, 1 of them phase 3. Brain Neoplasms · Northwell Health.

Planned enrollment
10th of 14
12 · median 30
Started
2026
the only one that year
No phase
5 of 14
4 open now
Registered
14th of 14
by date

Among the 14 studies in Brain Neoplasms by Northwell Health, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 5 with no phase, and was the 14th registered.

Brain Neoplasms

2,443 studies on the registry are indexed under Brain Neoplasms; 545 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

8 of the 14 studies in Brain Neoplasms by Northwell Health are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Brain Neoplasms by Northwell Health, or all of them as a file.
02

Study summary

This pilot study investigates a new approach for patients with metastatic cancer that has spread to the brain (brain metastases) who are already planned to receive both fractionated stereotactic radiosurgery (fSRS) and brain surgery as standard treatment for their condition. Usually, surgery comes first, followed by radiation. However, post-operative radiation can sometimes lead to the cancer returning in the area, spreading to the brain's lining (LMD), or causing side effects from radiation (RN). This study hypothesizes that delivering fSRS before surgery may improve outcomes by enabling more accurate targeting, reducing tumor spillage, and potentially decreasing RN, while improving treatment compliance. The study is specifically testing the sequence of these two standard treatments.

This is a single-arm, prospective study enrolling 12 adult participants (age >18) with 1-5 brain metastases, where one main tumor (between 2.0-5.0 cm diameter) requires surgical resection. Participants will receive fSRS (27 Gy in 3 fractions) approximately one week prior to surgery, as part of the study's approach. Throughout the study, participants will also have regular brain MRI scans to monitor their condition and complete tests to check memory and thinking skills (like the MoCA test) at various points.

The main goal is to see how well the cancer is controlled at the surgery site (called local freedom from progression, or FFP) over 6, 12, 18, and 24 months post-operatively. Secondary outcomes include rates of LMD and RN. Safety (adverse events, toxicities) will be continuously monitored by an independent Data Safety Monitoring Committee (DSMC). Each participant will be in the study for 2 years.

This research aims to provide preliminary data to inform future larger, randomized trials, ultimately improving treatment strategies for patients with metastatic brain cancer.

03

Conditions studied

  • Brain Metastasases

Keywords

  • Brain Metastases
  • Metastatic Cancer
  • Fractionated Stereotactic Radiosurgery
  • fSRS
  • Pre-Operative Radiation
  • Radiosurgery
  • Brain Cancer
  • Brain Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is ≥18 years old.
  • Radiographic confirmation of 1-5 by MRI with contrast obtained within 4 weeks prior to registration. One of these must be an index lesion requiring surgical resection.
  • The maximum diameter of the index lesion, as measured on any orthogonal plane (axial, sagittal, coronal) on the post-contrast MRI, must be ≥2.0 cm and ≤5.0 cm.
  • Documented pathological diagnosis of active or history of invasive cancer within the past 5 years.
  • All brain metastases must be located ≥5 mm from the optic chiasm and outside the brainstem.
  • Patient can medically tolerate surgery and fSRS. The treating surgeon must deem the index lesion an appropriate target for safe resection.
  • Performance Status (KPS) ≥50 within 14 days prior to registration.
  • A negative urine or serum pregnancy test (for individuals of ) ≤14 days prior to registration.
  • Patient or legally authorized representative provides study-specific before study entry. For patients treated in the U.S., authorization permitting release of personal health information is also required.

Exclusion criteria

Exclusion Criteria:

- Previous cranial radiotherapy, including whole-brain radiotherapy or stereotactic radiosurgery (SRS), to the planned resection site (index lesion). Repeat radiosurgery to the same location/lesion is not permitted on this protocol.

Note: Prior or current fSRS/SRS to other non-index lesions is allowed.

  • Evidence of .
  • Any or inability to undergo MRI with contrast.
  • Planned administration of cytotoxic chemotherapy or tyrosine/multi-kinase inhibitors within 3 days prior to, on the day of, or within 3 days after the completion of fSRS.

Note: Chemotherapy and immunotherapy outside of this window are allowed.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Pre-Operative fSRS Followed by Re-Section

    This arm consists of all enrolled participants who will receive fractionated stereotactic radiosurgery (fSRS) prior to neurosurgical resection of their brain metastasis. This approach investigates a modified sequence of two standard-of-care treatments for this condition, aiming to evaluate its safety and efficacy.

    Radiation: Fractionated Stereotactic Radiosurgery (fSRS) · Procedure: Neurosurgical Resection

Interventions

  • RadiationFractionated Stereotactic Radiosurgery (fSRS)

    Pre-operative fSRS to a dose of 27 Gy in 3 fractions will be delivered to the index lesion every other day. These radiation treatments will be completed within 1 week (+/- 5 days) prior to surgical resection. This is a standard radiation procedure for brain metastases.

  • ProcedureNeurosurgical Resection

    Surgical removal of the brain metastasis (index lesion) performed after completion of pre-operative fSRS. This is a standard surgical procedure for brain metastases.

    Also known as: Brain Metastasis Resection

06

What researchers measure

Primary outcomes

  1. Local Freedom from Progression (FFP) within the Resection Cavity

    The absence of new nodular contrast enhancement 2 mm or less from the resection cavity.

    Time frame: 6, 12, 18, and 24 Months Post-Operative

Secondary outcomes

  1. Incidence of Leptomeningeal Disease (LMD)

    Documented incidence of LMD on brain MRI imaging

    Time frame: From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years

  2. Incidence of Radiation Necrosis (RN)

    Documented incidence of RN on brain MRI imaging

    Time frame: From post-operative (48-72 hours after surgery) through every 3 months for 2 years

  3. Change in Neurocognitive Function

    Assessed using the Montreal Cognitive Assessment (MoCA) score

    Time frame: Baseline, Post-Operative Visit, and Every 3 Months for 2 Years

Other outcomes

  1. Correlation of Pathologic Information Between Primary Cancer and Resected Brain Metastasis

    Comparison of pathological characteristics of resected brain metastasis with the primary tumor

    Time frame: Between Surgery and Post-Operative Visit

  2. Correlation of Extent of Surgical Resection with Survival Outcomes

    Evaluation of the Association between extent of surgical resection and Progression-Free Survival (PFS) and Overall Survival (OS)

    Time frame: From study registration until 2 years post-operative or death

07

Study locations

1 site
08

References and documents

Publications

  • Shepard MJ, Sheehan JP. The Choice of Postoperative Stereotactic Radiosurgery After Resection of an Isolated Brain Metastasis. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):940. doi: 10.1016/j.ijrobp.2018.05.081. Epub 2019 Oct 24. No abstract available. PubMed 31668513 ↗
  • Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1040-1048. doi: 10.1016/S1470-2045(17)30414-X. Epub 2017 Jul 4. PubMed 28687375 ↗
  • Palmer JD, Perlow HK, Matsui JK, Ho C, Prasad RN, Liu K, Upadhyay R, Klamer B, Wang J, Damante M, Ghose J, Blakaj DM, Beyer S, Grecula J, Arnett A, Thomas E, Chakravarti A, Lonser R, Hardesty D, Prevedello D, Prabhu R, Elder JB, Raval RR. Fractionated pre-operative stereotactic radiotherapy for patients with brain metastases: a multi-institutional analysis. J Neurooncol. 2022 Sep;159(2):389-395. doi: 10.1007/s11060-022-04073-w. Epub 2022 Jun 25. PubMed 35751740 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — A formal plan for sharing individual participant data (IPD) has not been developed or approved for this pilot study. Participant confidentiality and privacy are strictly maintained, and study data will be transmitted and stored internally at the Northwell Health Cancer Institute (NHCI) in a de-identified format for statistical analysis and scientific reporting. Results will be disseminated through publications that do not contain identifying information.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 308 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 24 months is below that.

Counting every sponsor, half of 319 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 19, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948356
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion